ERBB2 and breast carcinoma: The results of the BELIS study, evaluating the overall safety and tolerability of subcutaneous (SC) trastuzumab administered at home for the treatment of patients with HER2-positive early breast cancer, indicated that trastuzumab SC was not associated with any new safety events.